Goldman Sachs
IBRX icon

Goldman Sachs’s ImmunityBio IBRX Stock Holding History

Goldman Sachs’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.8M Sell
3,237,078
-2,915,606
-47% -$20M ﹤0.01% 2222
2025
Q4 		$12.2M Buy
6,152,684
+5,012,001
+439% +$11.4M ﹤0.01% 2901
2025
Q3 		$2.81M Buy
1,140,683
+309,477
+37% +$797K ﹤0.01% 4178
2025
Q2 		$2.19M Sell
831,206
-225,693
-21% -$607K ﹤0.01% 4105
2025
Q1 		$3.18M Sell
1,056,899
-84,637
-7% -$257K ﹤0.01% 3786
2024
Q4 		$2.92M Sell
1,141,536
-147,371
-11% -$614K ﹤0.01% 3973
2024
Q3 		$4.79M Buy
1,288,907
+263,932
+26% +$1.22M ﹤0.01% 3377
2024
Q2 		$6.48M Sell
1,024,975
-190,406
-16% -$1.26M ﹤0.01% 2918
2024
Q1 		$6.53M Sell
1,215,381
-63,257
-5% -$286K ﹤0.01% 2859
2023
Q4 		$6.42M Buy
1,278,638
+850,874
+199% +$2.67M ﹤0.01% 2947
2023
Q3 		$723K Buy
427,764
+154,644
+57% +$311K ﹤0.01% 4458
2023
Q2 		$759K Sell
273,120
-80,441
-23% -$227K ﹤0.01% 4513
2023
Q1 		$643K Sell
353,561
-798,163
-69% -$2.48M ﹤0.01% 4685
2022
Q4 		$5.84M Buy
1,151,724
+585,881
+104% +$3.22M ﹤0.01% 3032
2022
Q3 		$2.81M Sell
565,843
-4,997
-0.9% -$22.8K ﹤0.01% 3661
2022
Q2 		$2.12M Buy
570,840
+162,665
+40% +$653K ﹤0.01% 3997
2022
Q1 		$2.29M Buy
408,175
+146,476
+56% +$899K ﹤0.01% 4138
2021
Q4 		$1.59M Buy
261,699
+35,952
+16% +$270K ﹤0.01% 4440
2021
Q3 		$2.2M Buy
225,747
+29,340
+15% +$323K ﹤0.01% 4113
2021
Q2 		$2.8M Buy
196,407
+115,265
+142% +$1.9M ﹤0.01% 3894
2021
Q1 		$1.93M Buy
81,142
+24,523
+43% +$636K ﹤0.01% 4021
2020
Q4 		$755K Sell
56,619
-1,081
-2% -$10.4K ﹤0.01% 4380
2020
Q3 		$400K Buy
+57,700
New +$575K ﹤0.01% 4599
2020
Q2 		– Sell
-80,447
Closed -$232K – 5327
2020
Q1 		$232K Buy
+80,447
New +$403K ﹤0.01% 4637
2019
Q3 		– Sell
-77,032
Closed -$79K – 5262
2019
Q2 		$79K Buy
+77,032
New +$88.9K ﹤0.01% 4965
2019
Q1 		– Sell
-78,821
Closed -$92K – 5279
2018
Q4 		$92K Buy
78,821
+42,870
+119% +$98.1K ﹤0.01% 5012
2018
Q3 		$133K Sell
35,951
-51,246
-59% -$162K ﹤0.01% 5046
2018
Q2 		$267K Buy
87,197
+27,403
+46% +$101K ﹤0.01% 4848
2018
Q1 		$233K Buy
59,794
+13,729
+30% +$60.2K ﹤0.01% 4914
2017
Q4 		$207K Buy
46,065
+2,807
+6% +$13.3K ﹤0.01% 5409
2017
Q3 		$237K Sell
43,258
-8,951
-17% -$55.2K ﹤0.01% 5650
2017
Q2 		$396K Sell
52,209
-14,908
-22% -$64.4K ﹤0.01% 5286
2017
Q1 		$238K Buy
67,117
+348
+0.5% +$1.72K ﹤0.01% 5616
2016
Q4 		$382K Buy
66,769
+35,811
+116% +$239K ﹤0.01% 5286
2016
Q3 		$241K Buy
30,958
+910
+3% +$6.8K ﹤0.01% 5662
2016
Q2 		$187K Sell
30,048
-61,761
-67% -$479K ﹤0.01% 5743
2016
Q1 		$755K Sell
91,809
-136,786
-60% -$1.29M ﹤0.01% 4333
2015
Q4 		$3.96M Buy
+228,595
New +$3.39M ﹤0.01% 3048

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Goldman Sachs's IBRX Position: Q1 2026 in Review

Goldman Sachs reduced its ImmunityBio (IBRX) stake by 47% in Q1 2026, selling an estimated $20M and leaving 3,237,078 shares worth $24.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2222.

Goldman Sachs first reported a position in IBRX in Q4 2015 and has held it in 38 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Goldman Sachs held 3,237,078 shares of ImmunityBio worth $24.8M as of Q1 2026.
  • Goldman Sachs sold 2,915,606 ImmunityBio shares in Q1 2026, an estimated $20M.
  • ImmunityBio made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2222 holding.
  • Goldman Sachs first reported a position in ImmunityBio in Q4 2015 and has held it in 38 quarters since.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.